AnaptysBio had its Relative Strength (RS) Rating upgraded from 69 to 76 Friday — a welcome improvement, but still shy of the 80 or higher score you prefer to see.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best-performing stocks often have an RS Rating of above 80 as they launch their largest runs. See if AnaptysBio can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
AnaptysBio is not currently near a potential buying area. See if the stock goes on to form a sound pattern that could spark a new run.
AnaptysBio showed 0% earnings growth in its most recent report. Sales rose 378%.
The company earns the No. 74 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
